Drug Profile
GSK 3008348
Alternative Names: GSK3008348Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antifibrotics
- Mechanism of Action Integrin alphaV antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in United Kingdom (Inhalation, Liquid)
- 04 Mar 2020 Adverse events, Pharmacokinetic and Efficay data from a phase Ib trial in Idiopathic pulmonary fibrosis presented at the 29th Annual Congress of the European Respiratory Society (ERS-2019)
- 08 Jan 2019 GlaxoSmithKline terminates phase I trial in Idiopathic pulmonary fibrosis in United Kingdom (Inhalation) (NCT03069989) (EudraCT2016-003674-41)